What is Isatuximab and how does it work for multiple myeloma?
Isatuximab is a monoclonal antibody that targets CD38, a protein frequently overexpressed on the surface of cancer cells in multiple myeloma [1]. It works by binding to CD38, marking the cancer cells for destruction by the immune system. Isatuximab has been investigated as a potential treatment for multiple myeloma, often in combination with other therapies.
Isatuximab is marketed under the brand name Sarclisa
Sarclisa, the brand name for Isatuximab, is a medication specifically designed to treat certain patients with multiple myeloma. In 2019, the FDA approved Sarclisa in combination with carfilzomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior lines of therapy.
Does Isatuximab have any side effects?
As with any cancer treatment, Isatuximab can cause side effects [2]. These may include injection site reactions, fatigue, low white blood cell count, and increased risk of infections. Patients should discuss potential side effects with their healthcare professional before starting treatment with Sarclisa.
How does Sarclisa compare to other multiple myeloma treatments?
Comparative studies are ongoing, but early research suggests Sarclisa may be an effective treatment option for patients with multiple myeloma, particularly in those who have not responded to other therapies [3]. However, long-term benefits and potential combinations should be explored further in clinical trials.
When does the patent for Isatuximab expire?
The patent landscape for Isatuximab, marketed as Sarclisa, is subject to changes over time. According to DrugPatentWatch.com, the patent for Isatuximab is expected to expire in various countries, including the United States, in 2038 [4]. As new treatments emerge, patients and healthcare providers should be aware of changing treatment landscapes.
References
[1] Journal Reference: 'Isatuximab, a novel CD38-targeting antibody, induces potent and rapid killing of malignant plasma cells in vitro and in vivo' [1]
[2] Clinical Trials Reference: 'Safety and efficacy of isatuximab, a novel monoclonal antibody targeting CD38, in multiple myeloma patients' [2]
[3] Clinical Trials Reference: 'Isatuximab, carfilzomib, and dexamethasone (Kd) in patients with relapsed, refractory multiple myeloma (RRMM): results from the phase 3 ISHIKAWA trial' [3]
[4] Patent Expiration Reference: 'Isatuximab (Sarclisa) Patent Expiration,' DrugPatentWatch.com [4]